Snehal Bhatt
@SnayCardsPharmD
Followers
891
Following
33K
Media
207
Statuses
2K
RT @DrMarthaGulati: Our statement is out:.2025 Concise Clinical Guidance: An @ACCinTouch Expert Consensus Statement on Medical Weight Manag….
0
55
0
RT @drbennisahmed: Heart failure and obesity: Translational approaches and therapeutic perspectives. A scientific statement of the Heart Fa….
0
8
0
RT @AHAScience: 1/ Cardiovascular diseases, including heart disease and stroke, claim more lives in the U.S. than all forms of cancer and a….
0
87
0
0
59
0
Friday AFib Fact: The risk of stroke can be reduced by 64% with treatment for #AFib! Learn more in our Rapid Resource "Untreated Patients with Atrial Fibrillation: Closing the Gaps in Stroke Prevention" > Thank you to editors/reviewers Arthur Allen,
0
1
5
It's an honor to moderate Clinical Pearls. Thanks for the shout out @phuiras and thanks to @ASHPOfficial for the opportunity 🙏🏽.
@SnayCardsPharmD is the best MC at the ASHP Pearls. So funny. Nice work! @ASHPOfficial.
0
0
11
RT @PharmacistHF: European Society of Clinical Pharmacy: ‘the prescribing pharmacist: a prescription for better patient care’.@IntJClinPhar….
0
8
0
RT @drbennisahmed: Rapid Uptitration of Guideline-Directed Medical Therapies in Acute Heart Failure With and Without Atrial Fibrillation. R….
0
11
0
RT @JonathanDavisHF: I missed this: great @JACCJournals review on GU infxn w SGLT2i. SGLT2i is assoc w⬆️risk of GMI but NOT UTI or Fournier….
0
21
0
RT @SeguraCardio: ✨Cardio-Oncology & Heart Failure: A Scientific Statement from the @HFSA‼️. #CardioOncology #HF #PositionPaper #Cancer htt….
0
59
0
RT @GBarnesMD: Check out this fun and engaging tweetorial that I put together discussing #cvCoag treatment options and current limitations….
0
6
0
Well said @keefer007! I feel so fortunate to be part of the #HMICommunity.
@HollyGoodMD and @SKWood8 and the entire @HarvardMacy team have put together an incredibly memorable part I of the educators course - what an amazing cohort of scholars and faculty. So privileged to be part of this family! Thank you so much!. #hmieducators #meded #hpe
0
0
1
Sodium-glucose cotransporter-2 inhibitors are recommended treatment for adults with CKD, but uncertainty exists regarding their use in patients with frailty and/or multimorbidity, among whom polypharmacy is common. These findings support the use of sodium-glucose cotransporter-2
0
0
2
RT @erin_barreto: Thanks for the feedback everyone, we were able to talk to the publisher and get the #AKIP list is open access for the wee….
journals.sagepub.com
The objective of this project was to develop a standardized list of renally eliminated and potentially nephrotoxic drugs that will help inform initiatives to im...
0
21
0
RT @AnticoagForum: Brush up on your knowledge of DOAC drug-drug interactions. Our newly updated Rapid Resource has you covered! This essent….
0
9
0
Never underestimate the power of clinical inertia. Other than cost, few barriers persistently exist in implementing GDMT.
Physician-Reported Reasons for Not Initiating Guideline-Directed Medical Therapy for Heart Failure. 85.4%patients were not prescribed quadruple therapy with angiotensin-converting enzyme inhibitor/ARB/ARNI, beta-blocker, MRA, or SGT2 inhibitor.
0
1
5
RT @gcfmd: MRA in HFrEF. RALES 1999 ⬇️ ☠️ HR 0.70 (0.60-0.83) p<0.001.EMPHASIS-HF 2010 ⬇️ ☠️ HR 0.76 (0.62-0.93) p=0.008. Class 1 in guidel….
0
26
0
At least 1 Factor Xi inhibitior is *NOT* ready for the big show in AF.
The OCEANIC-AF randomized trial of the factor XIa inhibitor asundexian was stopped early owing to a higher incidence of stroke or systemic embolism than with apixaban therapy among patients with atrial fibrillation. Full trial results: . #ESCardio
0
0
1
RT @PharmacistHF: More evidence combination DOAC & antiplatelet should not use used together in patients with Atrial Fibrillation and Stabl….
nejm.org
Despite consistent recommendations from clinical guidelines, data from randomized trials on a long-term antithrombotic treatment strategy for patients with atrial fibrillation and stable coronary a...
0
15
0